Hybridon Publishes Data on Novel Synthetic Agonists of Toll-Like Receptor 9
11 Mayo 2005 - 9:05AM
PR Newswire (US)
Hybridon Publishes Data on Novel Synthetic Agonists of Toll-Like
Receptor 9 CAMBRIDGE, Mass., May 11 /PRNewswire-FirstCall/ --
Hybridon, Inc. (AMEX: HBY) today announced the publication of
results of preclinical studies on novel DNA compounds, designed by
Hybridon, that activate TLR9 and induce distinct immune responses.
The results published in the recent issue of the Proceedings of the
National Academy of Sciences USA (PNAS) described immune
stimulation effects of representative proprietary compounds from
different classes of synthetic TLR9 agonists using cell-based
assays and studies in mice and monkeys. "The results of these
studies demonstrate our ability to identify novel synthetic DNA
agonists that can modulate immune responses through Toll-Like
receptors," commented Sudhir Agrawal, D.Phil., Chief Executive
Officer and Chief Scientific Officer of Hybridon. "As the TLR9
agonists are potentially applicable to treat a wide variety of
diseases including cancer, asthma, allergies, and infectious
disease, compounds that can create different immune responses may
be used to produce drug candidates that are more disease-
specific." Hybridon's lead compound, IMOxine(R), is in Phase II
clinical trials for Renal Cell Carcinoma. The paper entitled
'Immunomodulatory oligonucleotides containing a
cytosine-phosphate-2-deoxy-7-deazaguanosine motif as potent
Toll-like receptor 9 agonists' was published in the May 10th, 2005
issue of PNAS (vol. 102, pp 6925-6930). About Hybridon Hybridon,
Inc. is developing novel therapeutics based on synthetic nucleic
acid chemistry for the treatment of cancer, asthma/allergies, and
infectious diseases. Hybridon's proprietary IMO drug candidates are
designed to modulate immune responses through Toll-like receptors,
the body's first line of defense against disease. The Company's
nucleic acid chemistry expertise has also generated a portfolio of
partnered products and intellectual property, creating the
potential for long-term value for Hybridon. For more information
please visit our website at http://www.hybridon.com/. This press
release contains forward-looking statements concerning Hybridon
that involve a number of risks and uncertainties. For this purpose,
any statements contained herein that are not statements of
historical fact may be deemed to be forward-looking statements.
Without limiting the foregoing, the words "believes,"
"anticipates," "plans," "expects," "estimates," "intends,"
"should," "could," "will," "may," and similar expressions are
intended to identify forward-looking statements. There are a number
of important factors that could cause Hybridon's actual results to
differ materially from those indicated by such forward-looking
statements, including risks as to whether results obtained in
preclinical studies such as the studies referred to in this release
or early clinical trials will be indicative of results obtained in
future preclinical studies or clinical trials, or warrant further
clinical trials and product development; whether products based on
Hybridon's technology will advance through the clinical trial
process and receive approval from the United States Food and Drug
Administration or equivalent foreign regulatory agencies; whether,
if such products receive approval, they will be successfully
distributed and marketed; whether the patents and patent
applications owned or licensed by Hybridon will protect the
Company's technology and prevent others from infringing it; whether
Hybridon's cash resources will be sufficient to fund product
development; whether the Company's collaborations will be
successful; and such other important factors as are set forth under
the caption "Risk Factors" in Hybridon's Annual Report on Form 10-K
filed on March 25, 2005, which important factors are incorporated
herein by reference. Hybridon disclaims any intention or obligation
to update any forward-looking statements. Contacts: Hybridon, Inc.
MacDougall Biomedical Communications 617-679-5500, x5526
508-647-0209 x12 Tim Sullivan Douglas MacDougall E-mail: Email:
DATASOURCE: Hybridon, Inc. CONTACT: Tim Sullivan of Hybridon, Inc.,
+1-617-679-5500, ext. 5526, ; or Douglas MacDougall of MacDougall
Biomedical Communications, +1-508-647-0209 ext. 12, Web site:
http://www.hybridon.com/
Copyright